RS54834B1 - Jedinjenja pirazolokvinolina - Google Patents
Jedinjenja pirazolokvinolinaInfo
- Publication number
- RS54834B1 RS54834B1 RS20160364A RSP20160364A RS54834B1 RS 54834 B1 RS54834 B1 RS 54834B1 RS 20160364 A RS20160364 A RS 20160364A RS P20160364 A RSP20160364 A RS P20160364A RS 54834 B1 RS54834 B1 RS 54834B1
- Authority
- RS
- Serbia
- Prior art keywords
- alkyl
- alkylene
- halogen
- ring
- hetero
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Jedinjenje formule (I) ili njegova so:u kojojR1 predstavlja vodonik, halogen-C1-6alkil, C1-6alkil, ili -O-C1-6alkil,R2 je grupa formule (II):R3 predstavlja C1-6alkilen-(cikloalkil koji može biti supstituisan halogenom ili -O-C1-6alkilom); C1-6alkilen-zasićen hetero prsten sa sadržajem kiseonika; cikloalkil koji može biti supstituisan halogenom ili -O-C1-6alkilom; zasićeni hetero prsten sa sadržajem kisonika; ili monociklični zasićeni hetero prsten sa sadržajem azota koji može biti supstituisan C1-6alkilom, C1-6alkilen-arilom, ili -CO-C1-6alkilen-O-C1-6alkilom,R4, R5 i R6 su vodonik,Ra i Rb kombinovani su sa susednim atomom azota radi obrazovanja monocikličnog heteroprstena sa sadržajem azota, koji može biti supstituisan grupom odabranom između:-OH; halogen-C1-6alkil; -O-C1-6alkil koji može biti supstituisan sa 1 do 3 grupe odabrane iz grupe koja se sastoji od halogena, halogen-C1-6alkila i cikloalkila; aril koji može biti supstituisan grupom odabranom između grupe G1; heteroprstena koji može biti supstituisan grupom odabranom između grupe G2; C1-6alkilen-O-cikloalkila; -O-cikloalkila; -O-(hetero prsten koji može biti supstituisan grupom odabranom iz grupe G2); C1-6alkila koji može biti supstituisan sa jednom ili više grupa odabranih iz grupekoja se sastoji od halogena, halogen-C1-6alkila, -O-cikloalkila, -O-C1-6alkila i -O-halogen-C1-6alkila; i C1-6alkilen-O-C1-6alkil koji može biti supstituisan sa jednom ili više grupa odabranom iz grupe koja se sastoji od halogena, halogen-Ci-6 alkila i cikloalkila,grupa G1 sastoji se od halogena, C1-6alkila, halogen-C1-6alkila, -OH, -O-C1-6alkila, -O-hetero prstena, -O-C1-6alkilen-arila, -O-C1-6alkilen-hetero prstena, -O-halogen-C1-6alkila, -N(C1-6alkil)2, C1-6alkilen-N(C1-6alkil)2, C1-6alkilen-hetero prstena, arila koji može biti supstituisan C1-6alkilom, hetero prsten koji može biti supstituisan sa C1-6alkilom, -COOH, -CO-O-C1-6alkilom, -CO-O-C1-6alkilen-O-C1-6alkilom, -CO-O-C1-6alkilen-arilom, -CO-O-C1-6alkilen-O-arilom, -CO-NH2, -CO-NH-C1-6alkilom, -CO-N(C1-6alkil)2, -CO-N(C1-6alkil)-arilom, -CO-N(C1-6alkil)-hetero prstenom, -CO-N(C1-6alkil)-(C1-6alkilen-aril), -CO-NH-C1-6alkilen-OH i -CO-NH-hetero prstenom, agrupa G2 sastoji se od halogena, C1-6alkila, halogen-C1-6alkila, -OH, -O-C1-6alkila, -O-C1-6alkilen-arila, -O-C1-6alkilen-hetero prstena, -O-halogen-C1-6alkila, cijano, -N(C1-6alkil)2, -NH-CO-C1-6alkila, C1-6alkilen-O-C1-6alkila, C1-6alkilen-hetero prstena, arila, hetero prstena koji može biti supstituisan sa C1-6alkilom, -COOH, -CO-O-C1-6alkilom, -CO-O-C1-6alkilen-O-C1-6alkilom, -CO-O-C1-6alkilen-arilom, -CO-O-C1-6alkilen-O-arilom, -CO-NH2, -CO-NH-C1-6alkilom, -CO-N(C1-6alkil)2, -CO-N(C1-6alkil)-arilom, -CO-N(C1-6alkil)-hetero prstenom, -CO-N(C1-6alkil)-(C1-6alkilen-aril), -CO-NH-C1-6alkilen-OH i -CO-NH-hetero prstenomgde se "aril" odnosi na C6-14 monocikličnu do tricikličnu grupu prstena aromatičnog ugljovodonika, a pojam "hetero prsten" odnosi se na grupu prstena koja sadrži (i) monociklični 3-do 8-člani prsten sa 1 do 4 hetero atoma odabranih između kiseonika, sumpora i azota, ili (ii) bi-do triciklični prsten sa 1 do 5 hetero atoma odabranih između kiseonika, sumpora i azota, formiranu fuzijom prstena monocikličnog heteroprstena sa dva ili tri prstena odabranih iz grupe koja se sastoji od monocikličnog heteroprstena, benzenovog prstena, C5-8 cikloalkana i C5-8 cikloalkena.Prijava sadrži još 21 patentni zahtev.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010200403 | 2010-09-07 | ||
| PCT/JP2011/070410 WO2012033144A1 (ja) | 2010-09-07 | 2011-09-07 | ピラゾロキノリン化合物 |
| EP11823618.1A EP2615089B1 (en) | 2010-09-07 | 2011-09-07 | Pyrazoloquinoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54834B1 true RS54834B1 (sr) | 2016-10-31 |
Family
ID=45810740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160364A RS54834B1 (sr) | 2010-09-07 | 2011-09-07 | Jedinjenja pirazolokvinolina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8822448B2 (sr) |
| EP (1) | EP2615089B1 (sr) |
| JP (1) | JP5888237B2 (sr) |
| KR (1) | KR101860583B1 (sr) |
| CN (1) | CN103097383B (sr) |
| BR (1) | BR112013005444B1 (sr) |
| CA (1) | CA2810696C (sr) |
| CY (1) | CY1117547T1 (sr) |
| DK (1) | DK2615089T3 (sr) |
| EA (1) | EA023493B1 (sr) |
| ES (1) | ES2583528T3 (sr) |
| HR (1) | HRP20160473T1 (sr) |
| HU (1) | HUE028038T2 (sr) |
| MX (1) | MX2013002584A (sr) |
| PL (1) | PL2615089T3 (sr) |
| RS (1) | RS54834B1 (sr) |
| SI (1) | SI2615089T1 (sr) |
| WO (1) | WO2012033144A1 (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| DK2573073T3 (en) * | 2011-09-26 | 2015-01-19 | Sanofi Sa | Pyrazolquinolinonderivater, their preparation and therapeutic use thereof |
| US9169246B2 (en) * | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
| PE20141557A1 (es) * | 2011-10-07 | 2014-11-15 | Eisai Randd Man Co Ltd | Derivado de pirazoloquinolina |
| CN102786525B (zh) | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
| PE20151718A1 (es) | 2013-04-05 | 2015-11-22 | Eisai Randd Man Co Ltd | Compuestos piridinilpirazoloquinolina |
| KR101997955B1 (ko) * | 2013-04-05 | 2019-07-08 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체의 염, 및 이의 결정 |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AR102849A1 (es) * | 2015-03-09 | 2017-03-29 | Astellas Pharma Inc | Compuesto de piridina bicíclica |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG11201909595VA (en) | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| MX2019013198A (es) | 2017-06-01 | 2020-01-20 | Eisai R&D Man Co Ltd | Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9). |
| JP7269875B2 (ja) | 2017-06-01 | 2023-05-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体を含有するレビー小体病治療剤 |
| CN110603039B (zh) | 2017-06-01 | 2023-02-28 | 卫材R&D管理有限公司 | 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂 |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192768A (en) | 1990-09-14 | 1993-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Pyrazoloquinoline derivatives |
| JPH05132484A (ja) * | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
| KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE60317102T3 (de) | 2003-01-09 | 2010-02-18 | Astellas Pharma Inc. | Pyrrolopyridazinderivate |
| US20050245563A1 (en) | 2003-05-29 | 2005-11-03 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
| AU2006258461B2 (en) | 2005-06-14 | 2011-08-25 | Aska Pharmaceutical Co., Ltd. | Thienopyrimidine derivative |
| US7671069B2 (en) | 2006-03-30 | 2010-03-02 | Chemocentryx, Inc. | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 |
| EP2050739B1 (en) | 2006-08-08 | 2016-07-06 | ASKA Pharmaceutical Co., Ltd. | Quinazoline derivative |
| ES2536906T3 (es) | 2006-12-13 | 2015-05-29 | Aska Pharmaceutical Co., Ltd. | Derivado de quinoxalina |
| JPWO2008072778A1 (ja) | 2006-12-13 | 2010-04-02 | あすか製薬株式会社 | 尿路系疾患の処置剤 |
| BRPI0811280B8 (pt) | 2007-05-11 | 2021-05-25 | Pfizer | compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos |
| US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经***疾病中的用途 |
| US9259564B2 (en) | 2009-01-22 | 2016-02-16 | Avent, Inc. | Enteral feeding assembly with lock assembly |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
-
2011
- 2011-09-07 MX MX2013002584A patent/MX2013002584A/es active IP Right Grant
- 2011-09-07 PL PL11823618.1T patent/PL2615089T3/pl unknown
- 2011-09-07 ES ES11823618.1T patent/ES2583528T3/es active Active
- 2011-09-07 BR BR112013005444-1A patent/BR112013005444B1/pt active IP Right Grant
- 2011-09-07 HU HUE11823618A patent/HUE028038T2/en unknown
- 2011-09-07 EA EA201390353A patent/EA023493B1/ru not_active IP Right Cessation
- 2011-09-07 RS RS20160364A patent/RS54834B1/sr unknown
- 2011-09-07 EP EP11823618.1A patent/EP2615089B1/en active Active
- 2011-09-07 SI SI201130826A patent/SI2615089T1/sl unknown
- 2011-09-07 JP JP2012533012A patent/JP5888237B2/ja not_active Expired - Fee Related
- 2011-09-07 WO PCT/JP2011/070410 patent/WO2012033144A1/ja active Application Filing
- 2011-09-07 KR KR1020137005776A patent/KR101860583B1/ko active IP Right Grant
- 2011-09-07 DK DK11823618.1T patent/DK2615089T3/en active
- 2011-09-07 CA CA2810696A patent/CA2810696C/en active Active
- 2011-09-07 CN CN201180043183.XA patent/CN103097383B/zh active Active
-
2013
- 2013-03-07 US US13/788,907 patent/US8822448B2/en active Active
-
2016
- 2016-05-04 HR HRP20160473TT patent/HRP20160473T1/hr unknown
- 2016-05-24 CY CY20161100451T patent/CY1117547T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2615089A4 (en) | 2014-01-01 |
| EP2615089B1 (en) | 2016-04-27 |
| DK2615089T3 (en) | 2016-06-06 |
| CN103097383B (zh) | 2015-09-16 |
| SI2615089T1 (sl) | 2016-08-31 |
| MX2013002584A (es) | 2013-04-29 |
| WO2012033144A1 (ja) | 2012-03-15 |
| JPWO2012033144A1 (ja) | 2014-01-20 |
| JP5888237B2 (ja) | 2016-03-16 |
| US20130225553A1 (en) | 2013-08-29 |
| US8822448B2 (en) | 2014-09-02 |
| EP2615089A1 (en) | 2013-07-17 |
| CY1117547T1 (el) | 2017-04-26 |
| CA2810696C (en) | 2018-09-18 |
| BR112013005444A2 (pt) | 2017-09-19 |
| CN103097383A (zh) | 2013-05-08 |
| BR112013005444B1 (pt) | 2019-07-09 |
| HRP20160473T1 (hr) | 2016-07-29 |
| PL2615089T3 (pl) | 2016-10-31 |
| KR101860583B1 (ko) | 2018-05-23 |
| KR20130106358A (ko) | 2013-09-27 |
| CA2810696A1 (en) | 2012-03-15 |
| HUE028038T2 (en) | 2016-11-28 |
| EA023493B1 (ru) | 2016-06-30 |
| ES2583528T3 (es) | 2016-09-21 |
| EA201390353A1 (ru) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54834B1 (sr) | Jedinjenja pirazolokvinolina | |
| RS52605B (sr) | Benzoeve kiseline (1-fenil-2-piridin-4-il)-etil estri kao inhibitori fosfodiesteraze | |
| MY165585A (en) | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors | |
| RS51549B (sr) | Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima | |
| RS54702B1 (sr) | Pirazolohinolinski derivati kao inhibitori pde9 | |
| RS54708B1 (sr) | Ariletinil derivati | |
| RS52126B (sr) | Derivati azabifenilaminobenzoične kiseline kao inhibitori dehidrogenaze dihidroorotata (dhodh) | |
| RS54723B1 (sr) | Kondenzovani derivati imidazola koji su korisni kao ido inhibitori | |
| RS53301B (sr) | Jednjenja tioacetata, kompozicije i postupci korišćenja | |
| RS53830B1 (sr) | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze | |
| RS51970B (sr) | Triciklična jedinjenja i njihova upotreba kao modulatora glukokortikoidnih receptora | |
| RS54718B1 (sr) | Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u lečenju kancera | |
| RS51483B (sr) | 4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze | |
| RS54202B1 (sr) | Hinolin i hinoksalin derivati kao inhibitori kinaza | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| WO2010013567A1 (ja) | アミド誘導体、該アミド誘導体を含有する有害生物防除剤および有害生物の防除方法 | |
| RS53282B (sr) | Tieno (2,3-b) piridindion ampk aktivatori i njihove terapeutske upotrebe | |
| RS53903B1 (sr) | Etinil derivati kao pozitivni alosterni modulatori mglur5 | |
| RS52261B (sr) | Amidofenoksi indazoli kao korisni inhibitori c-met-a | |
| MX2012007060A (es) | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria. | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| AR084277A1 (es) | Compuestos utiles para el tratamiento del sida | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| RS52661B (sr) | Terapeutska sredstva |